Aetiology and outcome of generalized convulsive status epilepticus in elderly  by Jayalakshmi, Sita et al.
Seizure 29 (2015) 104–108Aetiology and outcome of generalized convulsive status epilepticus
in elderly
Sita Jayalakshmi a,*, Sudhindra Vooturi a, Ramesh Chepuru a, Sambit Sahu b,
Mohandas Surath a
aDepartment of Neurology, Krishna Institute of Medical Sciences, Hyderabad, India
bDepartment of Intensive Care, Krishna Institute of Medical Sciences, Hyderabad, India
A R T I C L E I N F O
Article history:
Received 9 January 2015
Received in revised form 25 February 2015







A B S T R A C T
Purpose: Convulsive status epilepticus (CSE) is a common neurologic emergency in elderly people. The
current study elaborates the clinical characteristics and outcome of CSE in elderly patients.
Methods: Analysis of data of generalized CSE patients, aged 60 years and above admitted at the
neurointensive care unit (NICU) was performed. The primary outcome for analysis was in-hospital
mortality. The study population was divided into groups based on progression of CSE and mortality to
analyze difference in study variables. Mortality of the group was analyzed using life tables.
Results: A total of 33 patients satisﬁed the inclusion criteria from medical records of 212 patients with
CSE. Mean age of the study population was 67.0  6.8 years; 69.7% were men. Acute symptomatic aetiology
was the commonest cause of CSE (60.6%); nine (27.3%) patients progressed to refractory status epilepticus
(RSE) of which ﬁve patients had prolonged RSE. The overall mortality was 18.2%. Complications of mechanical
ventilation and mean age were higher in patients who died. Though vascular aetiology was the leading cause
of CSE (39.3%), it was not associated with progression to RSE or mortality. Acute symptomatic aetiology
accounted for ﬁve out of the six deaths in the entire cohort.
Conclusion: Less than one-third of elderly patients with CSE progressed to RSE. Vascular aetiology, the
leading cause of generalized CSE in elderly, was not associated with progression to RSE and mortality.
Acute symptomatic aetiology was associated with high mortality.
 2015 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
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Up to 40% of all cases of status epilepticus (SE) have been
reported in people aged 60 years and above [1]. In nearly one-third
of the older patients, the ﬁrst seizure presents as SE [2]. The
incidence of SE in elderly is almost twice that of general population
[3]. The most common aetiology of SE in elderly includes
cerebrovascular disease, infection, degenerative disease, neoplasm
and trauma [4]. Potential precipitating factors may be inadequate
concentrations of antiepileptic medications, alcohol withdrawal,
electrolyte imbalances and metabolic derangements [5]. Status
epilepticus is nearly ﬁve times more common in elderly than
young adults [6]. Variations exist in the reported incidence of SE in
elderly with studies in Europe reporting an annual incidence of* Corresponding author at: Department of Neurology, Krishna Institute of
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report as high as 86 per 100,000 patients aged 60 years and above
[1]. Most of the studies included all the types of SE in the analysis.
However, little is known about the incidence of convulsive SE (CSE)
in elderly among developing countries.
Principles in the treatment of SE in elderly are different from
that employed in young adults [7]. In elderly, lower clearance rates
and leaner body mass results in higher serum concentrations of
anti-epileptic drugs (AEDs) [8]. High prevalence of co-morbid
conditions like cardiac disease, hypertension, diabetes among
elderly patients with SE is documented [7]. This increases the
chance of potential adverse events possibly through alterations in
mechanism of AEDs by medications prescribed for co-morbidities
[7]. Therefore, the treating physician should consider the
circumstances and aetiology. Encouragingly, pharmacotherapy if
started promptly, most of the patients respond well and also
lowers fatality rate [9].
Mortality due to SE is more common in elderly where people
aged between 60 and 79 years and those above 80 years had 36%
and 56% higher mortality than those aged under 50 yearsserved.
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outcome [3]. Towne et al. [3] have also reported 100% mortality
in elderly patients with SE secondary to anoxia, where manifesta-
tions of SE are subtle. In patients with ischaemic brain injury, SE is
shown to increase mortality by three times [11]. On the contrary,
mortality rates are lower in elderly SE patients with aetiology of sub-
therapeutic dosages of AEDs [12].
Most of the existing literature on the epidemiology, clinical
course and outcome of SE in elderly is from the developed world
and includes non-convulsive SE also. However, fastest growth in
the older age group has been revealed from both developed and
developing countries like India where CSE in elderly is likely to
become an important health problem [3,5]. The current study
elaborates the clinical characteristics and outcome of CSE in elderly
patients.
2. Material and methods
This open cohort was part of a larger epilepsy registry. Analysis
of data of elderly patients aged 60 years and above [10] with
generalized CSE admitted between May 2005, and November
2014 in the neurointensive care unit (NICU) of Krishna Institute of
Medical Sciences, a tertiary care referral centre at Hyderabad in
South India was performed. The study was approved after review
by the Institutional Ethics Committee.
Patients aged below 60 years of age, those with complex partial
SE, absence SE, simple partial SE, myoclonic SE, psychogenic SE,
hypoxia related SE and non-convulsive SE were excluded for data
analysis. The information about age, gender, duration of CSE,
associated co-morbidities, past history of epilepsy and/or CSE was
obtained. Aetiology of CSE was classiﬁed as acute symptomatic,
remote symptomatic, those with pre-existing epilepsy and
cryptogenic (cause undetermined) [13]. Acute symptomatic group
included patients with central nervous system (CNS) inﬂammatory
disease (presumed encephalitis, CNS infections), acute cerebro-
vascular CNS disease (ischaemic stroke, cortical sinus venous
thrombosis), and those with metabolic aetiologies.
2.1. Deﬁnitions
Status Epilepticus was deﬁned as seizures lasting for more than
5 min or recurrent epileptic activity over a period of more than
5 min without regain of pre-existing level of consciousness
[1]. Refractory SE (RSE) was deﬁned as SE resistant to one ﬁrst line,
and one second line AED, requiring general anaesthesia (GA)
[14]. Prolonged RSE was deﬁned as CSE that continues 24 h or more
after the onset of anaesthesia, including those cases in which the
CSE recurs on the reduction or withdrawal of anaesthesia [15,16]. If
SE recurred days after withdrawal of anaesthetic drugs and
warranted re-administration of similar drugs, the length of the
NICU stay included the seizure free days too. Presumed encepha-
litis was deﬁned as encephalopathy (depressed or altered level of
consciousness) lasting >24 h with fever, and seizures along with
one or more than one of the following symptoms: focal
neurological deﬁcits, cerebrospinalﬂuid (CSF) mononuclear pleo-
cytosis, electroencephalogram (EEG) or neuroimaging ﬁndings
consistent with encephalitis, after excluding systemic infective
causes [17] and metabolic etiologies. All patients had baseline, and
follow up CT/MRI brain.
2.2. Treatment
All the patients were treated according to established guide-
lines [15]. The initial treatment included benzodiazepines
(lorazepam or midazolam) followed by intravenous AEDs (pheny-
tion, phenobarbitone, sodium valproate or levetiracetam alone orin combination). For GA thiopental, midazolam infusion was used.
Continuous EEG monitoring was performed in 28 patients
(including all patients who progressed to RSE). Appropriate
management of the underlying medical/neurological condition
was done.
2.3. Complications and outcome
Severe sepsis, acute kidney injury and acute hepatic failure
were deﬁned according to established guidelines [18]. The
outcome was classiﬁed as death or discharge from the hospital.
2.4. Statistical analysis
After testing for the normal distribution of the data, the study
population was divided into two groups based on progression of
CSE and mortality. Differences between the groups for continuous
variables were analyzed using independent Student’s t-test,
accounting for variance amongst group using Levene’s test for
equality of variance. Categorical variables were analyzed using chi-
square test. A p < 0.05 was considered signiﬁcant. Mortality of the
group was analyzed using life tables. Statistical Package for Social
Sciences (SPSS, ver. 17.0, IBM computers, New York, USA) was used
for all statistical analysis.
3. Results
3.1. Demographic and clinical characteristics
During the study period, a total of 212 patients were admitted
to the NICU with a diagnosis of CSE; of which, 33 (15.5%) were
patients aged 60 years and above. The mean age of the study
population was 67.0  6.8 years; 69.7% were men. Six patients were
aged 75 years and above. More than one third of the patients (36.3%)
in the study group were known diabetics and nearly half (48.5%) of
them were hypertensive. Nine (27.3%) patients progressed to RSE of
which ﬁve patients had prolonged RSE (Table 1). There were no
signiﬁcant differences between CSE and RSE groups for demographic
characteristics (Table 1). However, the mean age of patients who died
was higher (65.9  5.9 years vs. 71.8  9.0 years; p = 0.05), the
differences between groups divided based on mortality is summa-
rized in Table 3.
3.2. Aetiology
Acute symptomatic aetiology accounted for 20 cases (60.6%);
ﬁve had ischaemic stroke and one patient had cortical venous
thrombosis. Thirteen (39.3%) patients had CNS vascular aetiology
(ischaemic infarcts in 12 and cortical sinus venous thrombosis in
one) and another eight had metabolic aetiology. Six (18.2%)
patients had an aetiology of infections of CNS. Focal cerebral
calciﬁcation and gliosis were observed in one patient each.
Amongst the remote symptomatic group, seven patients had
vascular aetiology. Aetiology did not differ when the study
population was divided into groups based on progression of SE
(Table 1) and mortality (Table 3). Acute symptomatic aetiology, did
not increase the odds of progression of SE to RSE (OR 1.33, 95% CI
0.28–6.30; p = 0.509). Similarly, vascular aetiology also did not
increase the odds of progression to RSE (OR 2.96, 95% CI 0.50–
17.29; p = 0.263).
3.3. Clinical course and complications
In the entire cohort, 12 patients required mechanical ventila-
tion of whom six had evidence of pneumonia. The mean duration of
mechanical ventilation was 36  6.7 days in the entire cohort. The
Table 1
Comparison of clinical characteristics between groups based on progression of convulsive status epilepticus.
S. No Variable RSE (n = 9) NRSE (n = 24) p-value
1 Age (Years) 68.3  8.3 66.5  6.3 0.504
2 Men (%) 5 (55.6%) 18 (75.0%) 0.400
3 Hypertensive (%) 6 (66.7%) 10 (41.7%) 0.259
4 Diabetics (%) 2 (22.2%) 10 (41.7%) 0.429
5 Acute symptomatic aetiology (%) 5 (55.6%) 15 (62.5%) 1.000
Vascular 1 (11.1%) 5 (20.8%) 1.000
Central nervous system tuberculosis 0 (0.0%) 2 (8.4%) 1.000
Neurocysticercosis 0 (0.0%) 1 (4.2%) 1.000
Presumed encephalitis 2 (22.2%) 1 (4.2%) 0.173
Metabolic 2 (22.2%) 6 (25.0%) 1.000
6 Remote symptomatic aetiology (%) 3 (33.3%) 6 (25.0%) 0.676
Vascular 1 (11.1%) 6 (0.0%) 0.641
Focal cerebral calciﬁcation 1 (11.1%) 0 (0.0%) 0.272
Gliosis 1 (11.1%) 0 (0.0%) 0.272
7 Cryptogenic aetiology (%) 1 (11.1%) 0 (0.0%) 0.272
8 Past history of epilepsy present (%) 0 (0.0%) 3 (12.5%) 0.544
RSE – refractory status epilepticus; NRSE – non-refractory status epilepticus.
Table 2
Comparison for clinical course and outcome between groups based on progression of convulsive status epilepticus.
S. No Variable RSE (n = 9) NRSE (n = 24) p-value
1 Severe sepsis (%) 3 (33.3%) 1 (4.2%) 0.052
2 Acute kidney injury (%) 2 (22.2%) 0 (0.0%) 0.068
3 Acidosis (%) 3 (33.3%) 0 (0.0%) 0.015
4 Duration of mechanical ventilation (No. of days) 10.4  9.3 1.0  2.8 0.017
5 Duration in Neuro intensive care unit (No. of days) 12.8  10.3 4.6  3.4 0.046
6 Duration of hospital stay (No. of days) 16.4  11.2 7.1  3.9 0.039
7 Mortality (%) 4 (44.4%) 2 (8.3%) 0.034
RSE – refractory status epilepticus; NRSE – non-refractory status epilepticus.
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progressed to RSE 10.4  9.3 days vs. 1.0  2.8 days; p = 0.017).
However, duration of mechanical ventilation did not differ between
groups based on mortality (2.1  4.3 days vs. 10.3  11.2 days;
p = 0.13). Patients with RSE had signiﬁcantly higher incidence of
complications of mechanical ventilation like severe sepsis (33.3% vs.
4.2%; p = 0.052) and acidosis (33.3% vs. 0.0%; p = 0.015), summarized
in Table 2. Similarly, complications of mechanical ventilation were
higher in patients who died (Table 3). The average length of stay in
NICU was higher in RSE patients (12.8  10.3 days vs. 4.6  3.4 days;
p = 0.046) and those who died (5.6  5.7 days vs. 12.5  9.9 days;
p = 0.029).Table 3
Comparison between groups based on mortality.
S. No Variable 
1 Age (years) 
2 Men (%) 
3 Hypertensive (%) 
4 Diabetics (%) 
5 Acute symptomatic aetiology (%) 
6 Remote symptomatic aetiology (%) 
7 Idiopathic aetiology (%) 
8 Known epileptics (%) 
9 Vascular aetiology (%) 
10 Metabolic aetiology (%) 
11 Tuberculosis meningitis (%) 
12 Encephalitis (%) 
13 Refractory status epilepticus (%) 
14 Severe sepsis (%) 
15 Acute kidney injury (%) 
16 Acidosis (%) 
17 Requirement for mechanical ventilation (%) 
18 Duration in Neuro intensive care unit (No. of days) 
19 Duration of hospital stay (No. of days) 3.4. Outcome and survival analysis
Overall mortality was 18.2%, highest in RSE (44.4% vs. 8.3%;
p = 0.034). Acute symptomatic aetiology accounted for ﬁve out of
the six deaths in the entire cohort. Among non-survivors with
acute symptomatic aetiology, infections of CNS were observed in
three patients. Though vascular aetiology was the leading cause of
CSE (39.3%), none of the patients with vascular aetiology died. Five
of the six deaths happened in the ﬁrst 14 days where as the sixth
death was reported at the end of ﬁfth week (Fig. 1). In those who
survived 15 patients recovered and 12 remained the same at
discharge.Alive (n = 27) Dead (n = 6) p-value
65.9  5.9 71.8  9.0 0.055
21 (77.8%) 2 (33.3%) 0.053
13 (48.1%) 3 (50.0%) 1.000
10 (37.0%) 2 (33.3%) 1.000
15 (55.6%) 5 (83.3%) 0.364
8 (29.6%) 1 (16.7%) 1.000
1 (3.7%) 0 (0.0%) 1.000
3 (11.1%) 0 (0.0%) 1.000
13 (29.6%) 0 (0.0%) 0.060
6 (22.2%) 2 (33.3%) 0.616
1 (3.7%) 1 (16.7%) 0.335
1 (3.7%) 2 (33.3%) 0.079
5 (18.4%) 4 (66.7%) 0.034
1 (3.7%) 3 (50.0%) 0.014
0 (0.0%) 2 (33.3%) 0.028
0 (0.0%) 3 (50.0%) 0.004
8 (29.6%) 5 (83.3%) 0.025
5.6  5.7 12.5  9.9 0.029
8.8  7.2 13.6  9.7 0.171
Fig. 1. Chronology of deaths.
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The current study evaluates clinical characteristics and
outcome of generalized CSE in elderly patients from a developing
country. The ﬁndings of our study suggest that acute symptomatic
aetiology is not only common in elderly patients with CSE but also
accounts for most of the deaths. Furthermore, non-survivors have a
mean age higher than the survivors. Further research is necessary
to evaluate the factors contributing to outcome in elderly patients
with CSE.
4.1. Demographic characteristics and aetiology
The prevalence of diabetes mellitus and hypertension in the
current study is similar to that reported by Treiman et al., in a
multicentre Veteran Affairs study [19]. Consistent with existing
evidence [20,21], acute symptomatic aetiology has been the most
frequent cause of CSE in the current cohort; furthermore, vascular
aetiology followed by metabolic aetiologies were the leading
causes of CSE in the current study. The incidence of CSE in patients
with acute stroke is similar to that reported in Richmond study [6].
4.2. Clinical course and complications
As anticipated, the duration of stay in the NICU was longer in
patients who progressed to RSE, where all RSE patients required
mechanical ventilation. Consequently, the complications of
mechanical ventilation were higher in patients who progressed
to RSE, this is similar to the observations we reported earlier in
children and adult patients with CSE [22,23]. However, the
duration on mechanical ventilation and duration of hospital stay
did not differ between survivors and those who succumbed. This
probably may be attributed to our ﬁndings that non-survivors had
high prevalence of complications of mechanical ventilation and
thus leading to early mortality. In developing countries with
limited resources, referral to tertiary care centres is often delayed
due to failure to recognize early the severity of underlying cause ofCSE and associated injuries. Logistics involved in obtaining the data
regarding delay in referral or presentation was out of scope of the
current study.
4.3. Outcome and survival analysis
The overall mortality in the current study, done exclusively in
elderly patients with generalized CSE was 18.2%. Chin et al. [24]
previously reported a short term mortality up to 22% in patients
with CSE, with the highest recorded in elderly. In contrast, Sinha
et al. [25] reported mortality of 7.9% in elderly patients with new
onset SE from India, the study attributed presence of treatable
underlying cause and early therapy for reported lower mortalities.
Mortality reported previously by larger studies in the developed
world were epidemiological studies reported with inclusion of
patients with other types of SE like partial SE and non-convulsive
SE [10]. Seizure duration is strongly associated with mortality in
elderly patients with SE [3].
The current study included elderly patients with generalized
CSE only, and was performed in NICU of well-equipped tertiary
referral centres, managed by experienced intensivists and senior
neurologists, hence early identiﬁcation of CSE may have helped
reduce mortality reported. Our ﬁndings of high mortality
associated with acute symptomatic aetiology are consistent with
those reported by Annergers et al. [10]. Similarly, mortality rates
in the current study in patients with metabolic cause is similar to
that reported previously [26]. We also report that though vascular
aetiology was the leading cause of CSE (39.3%), it did not
contribute in progression to RSE, more importantly none of the
patients with vascular aetiology died at discharge from hospital.
Although these ﬁndings are encouraging, evaluation of long term
outcomes in elderly patients with CSE due to vascular aetiology
are desirable.
Our study reports a higher incidence of RSE, requirement of
mechanical ventilation and sepsis in non-survivors, consistent
with previous studies that evaluated the affect of infection on
mortality and length of stay in intensive care unit among SE
patients [27].
4.4. Strengths and limitations
Our study is one of the few series on CSE in elderly patients from
the developing world and reﬂects true clinical practice. However
our analysis may have been under powered to detect few
associations in individual groups. There may be a selection bias,
and under estimation of patients as cases of CSE from NICU only
were included in the study and many cases of might have
responded well at emergency room. We could not ascertain the
exact of duration of CSE prior to admission, as delay in initiation of
treatment in SE may inﬂuence the duration, and outcome of CSE.
Our ﬁndings are predominantly single factor association, and
should be carefully interpreted; however the ﬁndings seem to be
clinically plausible.
5. Conclusion
Less than one-third of elderly patients with CSE progressed to
RSE. Vascular aetiology, the leading cause of generalized CSE in
elderly, was not associated with progression of CSE to RSE and
mortality. Acute symptomatic aetiology was associated with high
mortality.
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